Piper Sandler Brokers Lower Earnings Estimates for Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) – Piper Sandler decreased their Q4 2021 earnings per share (EPS) estimates for Gilead Sciences in a report released on Monday, September 14th. Piper Sandler analyst T. Van. Buren now anticipates that the biopharmaceutical company will earn $1.75 per share for the quarter, down from their previous forecast of $1.80. Piper Sandler currently has a “Overweight” rating and a $83.00 price objective on the stock. Piper Sandler also issued estimates for Gilead Sciences’ FY2022 earnings at $8.15 EPS, FY2023 earnings at $8.70 EPS and FY2024 earnings at $10.60 EPS.

A number of other research firms have also recently issued reports on GILD. ValuEngine raised shares of Gilead Sciences from a “strong sell” rating to a “sell” rating in a report on Monday, August 3rd. Jefferies Financial Group decreased their price target on shares of Gilead Sciences from $97.00 to $78.00 in a report on Wednesday, August 19th. Citigroup raised their price target on shares of Gilead Sciences from $78.00 to $80.00 in a report on Monday, August 3rd. SVB Leerink decreased their price target on shares of Gilead Sciences from $94.00 to $88.00 and set an “outperform” rating for the company in a report on Monday. Finally, JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Friday, August 7th. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $78.78.

NASDAQ GILD opened at $65.65 on Wednesday. The company has a fifty day simple moving average of $67.58 and a two-hundred day simple moving average of $73.83. The stock has a market cap of $82.31 billion, a P/E ratio of -273.53, a P/E/G ratio of 0.67 and a beta of 0.56. Gilead Sciences has a 12-month low of $60.89 and a 12-month high of $85.97. The company has a current ratio of 2.33, a quick ratio of 2.23 and a debt-to-equity ratio of 1.22.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.11 EPS for the quarter, missing the Zacks’ consensus estimate of $1.57 by ($0.46). The firm had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.24 billion. Gilead Sciences had a negative net margin of 1.16% and a positive return on equity of 33.59%.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be given a dividend of $0.68 per share. The ex-dividend date is Monday, September 14th. This represents a $2.72 annualized dividend and a yield of 4.14%. Gilead Sciences’s dividend payout ratio is presently 44.30%.

A number of hedge funds have recently added to or reduced their stakes in the stock. Twin Focus Capital Partners LLC grew its position in Gilead Sciences by 2.1% during the first quarter. Twin Focus Capital Partners LLC now owns 6,537 shares of the biopharmaceutical company’s stock valued at $489,000 after buying an additional 137 shares during the period. Malaga Cove Capital LLC grew its position in shares of Gilead Sciences by 0.6% in the second quarter. Malaga Cove Capital LLC now owns 24,813 shares of the biopharmaceutical company’s stock valued at $1,909,000 after purchasing an additional 143 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its position in shares of Gilead Sciences by 4.2% in the first quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 3,605 shares of the biopharmaceutical company’s stock valued at $270,000 after purchasing an additional 144 shares during the period. Anderson Fisher LLC grew its position in shares of Gilead Sciences by 0.9% in the second quarter. Anderson Fisher LLC now owns 17,237 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 149 shares during the period. Finally, Archford Capital Strategies LLC grew its position in shares of Gilead Sciences by 1.5% in the second quarter. Archford Capital Strategies LLC now owns 9,912 shares of the biopharmaceutical company’s stock valued at $763,000 after purchasing an additional 149 shares during the period. Institutional investors own 77.87% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Further Reading: Trading Ex-Dividend

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.